ByteDance's drug discovery unit, Anew Labs, has presented its first AI-designed therapy at a major immunology conference in Boston, showing a small molecule designed by generative AI to inhibit IL-17, a protein-protein interaction long considered undruggable. The company also published AnewOmni, a generative framework trained on 5 million biomolecular complexes that claims to be the first to design functional molecules across all scales. The firm that built TikTok’s recommendation algorithm, which predicts what a person wants to watch next, is now using a related class of AI to predict how molecules will behave inside a human body. The presentation in Boston was the first time ByteDance showed what its drug unit has built and will not be the last time it will showcase its AI capabilities.